Leucine supplementation attenuates macrophage foam-cell formation: Studies in humans, mice, and cultured macrophages

Biofactors. 2018 May;44(3):245-262. doi: 10.1002/biof.1415. Epub 2018 Feb 5.

Abstract

Whereas atherogenicity of dietary lipids has been largely studied, relatively little is known about the possible contribution of dietary amino acids to macrophage foam-cell formation, a hallmark of early atherogenesis. Recently, we showed that leucine has antiatherogenic properties in the macrophage model system. In this study, an in-depth investigation of the role of leucine in macrophage lipid metabolism was conducted by supplementing humans, mice, or cultured macrophages with leucine. Macrophage incubation with serum obtained from healthy adults supplemented with leucine (5 g/d, 3 weeks) significantly decreased cellular cholesterol mass by inhibiting the rate of cholesterol biosynthesis and increasing cholesterol efflux from macrophages. Similarly, leucine supplementation to C57BL/6 mice (8 weeks) resulted in decreased cholesterol content in their harvested peritoneal macrophages (MPM) in relation with reduced cholesterol biosynthesis rate. Studies in J774A.1 murine macrophages revealed that leucine dose-dependently decreased cellular cholesterol and triglyceride mass. Macrophages treated with leucine (0.2 mM) showed attenuated uptake of very low-density lipoproteins and triglyceride biosynthesis rate, with a concurrent down-regulation of diacylglycerol acyltransferase-1, a key enzyme catalyzing triglyceride biosynthesis in macrophages. Similar effects were observed when macrophages were treated with α-ketoisocaproate, a key leucine metabolite. Finally, both in vivo and in vitro leucine supplementation significantly improved macrophage mitochondrial respiration and ATP production. The above studies, conducted in human, mice, and cultured macrophages, highlight a protective role for leucine attenuating macrophage foam-cell formation by mechanisms related to the metabolism of cholesterol, triglycerides, and energy production. © 2018 BioFactors, 44(3):245-262, 2018.

Keywords: foam-cell formation; leucine; lipid metabolism; macrophages; α-ketoisocaproate.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adenosine Triphosphate / agonists
  • Adenosine Triphosphate / biosynthesis
  • Adolescent
  • Adult
  • Animals
  • Anticholesteremic Agents / pharmacology*
  • Cell Differentiation / drug effects
  • Cell Line
  • Cholesterol / biosynthesis
  • Cholesterol, VLDL / antagonists & inhibitors
  • Cholesterol, VLDL / biosynthesis
  • Diacylglycerol O-Acyltransferase / antagonists & inhibitors
  • Diacylglycerol O-Acyltransferase / metabolism
  • Dietary Supplements*
  • Dose-Response Relationship, Drug
  • Foam Cells / cytology
  • Foam Cells / drug effects*
  • Foam Cells / metabolism
  • Healthy Volunteers
  • Humans
  • Keto Acids / pharmacology*
  • Leucine / pharmacology*
  • Macrophages / cytology
  • Macrophages / drug effects*
  • Macrophages / metabolism
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Middle Aged
  • Mitochondria / drug effects
  • Mitochondria / metabolism
  • Oxidative Phosphorylation / drug effects
  • Triglycerides / antagonists & inhibitors
  • Triglycerides / biosynthesis

Substances

  • Anticholesteremic Agents
  • Cholesterol, VLDL
  • Keto Acids
  • Triglycerides
  • alpha-ketoisocaproic acid
  • Adenosine Triphosphate
  • Cholesterol
  • Diacylglycerol O-Acyltransferase
  • Leucine